News & Updates

Back to All News

Bryn Mawr Hospital, Lankenau Heart Institute, is first in PA to offer breakthrough treatment for central sleep apnea with remede® System

Bryn Mawr Hospital March 26, 2019 News Releases

Bryn Mawr Hospital, a member of Main Line Health’s Lankenau Heart Institute, is the first in Pennsylvania to offer adult patients with moderate to severe central sleep apnea with the newly approved remede® System, a breakthrough treatment that has been shown to improve sleep, breathing and quality of life.

“We are thrilled to be the first commercial implant in Pennsylvania and, since market release, among the first commercial implants in the U.S. outside the FDA approval process to offer this new treatment option to patients suffering with moderate to severe central sleep apnea,” says Sheetal Chandhok, MD, Lankenau Heart Institute cardiologist and electrophysiologist at Bryn Mawr Hospital. “This implantable system can monitor and stabilize the breathing pattern to restore sleep throughout the night—offering critical benefits to patients’ overall cardiovascular health and quality of life.”

Patients who are suffering from central sleep apnea can experience many symptoms, including excessive daytime sleepiness, reduced exercise capacity, hypoxia (decrease in blood oxygen level), and irregular or very fast heart rhythms (arrhythmia). Studies have shown that untreated central sleep apnea is a significant contributor to lowered quality of life and contributes to poor cardiovascular outcomes such as worsening heart failure.

The remede® System stimulates a nerve in the chest—the phrenic nerve—to send signals to the diaphragm, the large muscle that controls breathing. These signals stimulate breathing in the same way that the brain would. The system is placed by a cardiologist during a minimally invasive outpatient procedure. The procedure typically takes an average of two to three hours and is performed under light sedation. Most patients are able to go home after a one-night stay in the hospital.

“Offering this new treatment option to patients with sleep apnea—a large population of patients in need of relief—truly reflects our commitment to advance cardiovascular care in our communities and throughout the Philadelphia region and beyond,” says William Gray, MD, chief of cardiovascular diseases at Lankenau Heart Institute, part of Main Line Health.

About Main Line Health

Founded in 1985, Main Line Health is a not-for-profit health system serving portions of Philadelphia and its western suburbs. Main Line Health’s commitment—to deliver advanced medicine to treat and cure disease while also playing an important role in prevention and disease management as well as training physicians and other health care providers—reflects our intent to keep our community and ourselves well ahead. A team of more than 10,000 employees and 2,000 physicians care for patients throughout the Main Line Health system.

At Main Line Health’s core are four of the region’s most respected acute care hospitals—Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital—as well as one of the nation’s recognized facilities for rehabilitative medicine, Bryn Mawr Rehabilitation Hospital.

The Main Line Health system also includes Mirmont Treatment Center for drug and alcohol recovery; Main Line Health HomeCare & Hospice, which includes skilled home health care, hospice and home infusion services; Main Line Health Centers, primary and specialty care, lab and radiology, and other outpatient services located in Broomall, Collegeville, Concordville, Exton and Newtown Square; Lankenau Institute for Medical Research, a biomedical research organization; and Main Line HealthCare, one of the region’s largest multispecialty physician networks.

Main Line Health is the recipient of numerous awards for quality care and service, including System Magnet® designation, the nation’s highest distinction for nursing excellence, the Mid-Atlantic Alliance for Performance Excellence (MAAPE) Excellence Award, and recognition as among the nation’s best employers by Forbes magazine. Main Line Health is committed to creating an environment of diversity, respect and inclusion and has proudly embraced the American Hospital Association’s #123forEquity Pledge to Act to eliminate disparities in care. We are dedicated to advancing patient-centered care, education and research to help our community stay healthy.

About Lankenau Heart Institute

The Lankenau Heart Institute is Main Line Health’s premier, comprehensive cardiovascular medicine and surgery program. The Lankenau Heart Institute brings together the clinical expertise of all four Main Line Health acute care hospitals and community cardiology practices to ensure that patients receive a level of quality, service, and experience that is unprecedented in the region. Through the system-wide coordination of services, the Lankenau Heart Institute delivers preventive, diagnostic, therapeutic, and rehabilitative cardiovascular services at each of our locations including Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital.

With a collaborative team of expert consultative cardiologists, interventional cardiologists, electrophysiologists, cardiovascular surgeons and specially trained nurses and technologists, the Lankenau Heart Institute is dedicated to managing and treating patients with heart failure, aortic disease, coronary and peripheral vascular disease, heart rhythm disorders and valve disease. Our team of cardiologists and cardiac specialists provide patients and their families with expert cardiac care, close to home.

About the remede® System

The remede® System is an implantable system that monitors and stabilizes the breathing pattern to restore sleep throughout the night. The remede System stimulates a nerve in the chest (phrenic nerve) that sends signals to the large muscle that controls breathing (the diaphragm). The remede System pivotal trial, published in The Lancet, demonstrated that transvenous neurostimulation with the remede System has been shown to significantly reduce the number of sleep apnea events for 87 percent of patients, improve quality of life for 79 percent of patients, and reported that 96 percent of patients would “elect to have the medical procedure again”

The remede System received U.S. Food and Drug Administration approval in October of 2017 and is commencing market release of the system in the United States at select hospitals.

About Respicardia

Respicardia is a private medical technology company dedicated to improving the lives of patients by developing implantable therapies designed to improve respiratory and cardiovascular health. The company’s initial product, the remede System, is an implantable neurostimulation system designed to restore a more normal breathing pattern during sleep for moderate to severe central sleep apnea adult patients.

Contact

Mary Kate Coghlan
Communications Specialist
Office: 484.580.1028
Cell: 610.308.6675
coghlanm@mlhs.org